Influenza Vaccination Strategies in Patients with Hematologic Cancer

In a randomized, controlled trial conducted across influenza seasons in the Southern Hemisphere (2022–2023), researchers compared two doses of adjuvanted versus standard-dose quadrivalent inactivated influenza vaccine (QIV) in 130 patients with hematologic cancers, including multiple myeloma, chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma. The primary outcome, seroconversion at one month after the second dose, showed no immunogenic benefit of adjuvanted over standard-dose QIV. Seroconversion rates remained particularly low in patients with CLL and non-Hodgkin’s lymphoma, likely due to B-cell-depleting therapies. The study suggests prioritizing single-dose QIV annually and emphasizes improving vaccination uptake rather than dose intensification

In a randomized, controlled trial conducted across influenza seasons in the Southern Hemisphere (2022–2023), researchers compared two doses of adjuvanted versus standard-dose quadrivalent inactivated influenza vaccine (QIV) in 130 patients with hematologic cancers, including multiple myeloma, chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma. The primary outcome, seroconversion at one month after the second dose, showed no immunogenic benefit of adjuvanted over standard-dose QIV. Seroconversion rates remained particularly low in patients with CLL and non-Hodgkin’s lymphoma, likely due to B-cell-depleting therapies. The study suggests prioritizing single-dose QIV annually and emphasizes improving vaccination uptake rather than dose intensification